Clinical Trial Update: Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction [Phase 2]

View source ↗

Summary

Phase 2 safety study of allogeneic mesenchymal precursor cell infusion in patients with acute myocardial infarction has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• Mesoblast Mesenchymal Precursor Cells (allogeneic mesenchymal precursor cells)

Snippet

Sponsor: Mesoblast, Inc. | Conditions: Acute Myocardial Infarction | Phase 2 | Status: COMPLETED | Results posted: 2022-01-18